Initiator Pharma A/S (INIT.ST)
SEK 6.36
(1.92%)
SEK 6.36
(1.92%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.69 Million DKK | 66.97% |
| 2022 | -26.33 Million DKK | -26.27% |
| 2021 | -20.85 Million DKK | -56.76% |
| 2020 | -13.3 Million DKK | -80.71% |
| 2019 | -7.36 Million DKK | 48.49% |
| 2018 | -14.29 Million DKK | -105.07% |
| 2017 | -6.96 Million DKK | -4073.05% |
| 2016 | -167 Thousand DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -18.76 Million DKK | -115.66% |
| 2024 Q2 | -14.48 Million DKK | 22.78% |
| 2023 Q1 | -21.01 Million DKK | 20.22% |
| 2023 FY | -8.69 Million DKK | 66.97% |
| 2023 Q4 | -8.69 Million DKK | -39.05% |
| 2023 Q3 | -6.25 Million DKK | 51.9% |
| 2023 Q2 | -13 Million DKK | 38.1% |
| 2022 Q2 | -16.17 Million DKK | -23.86% |
| 2022 Q3 | -33.47 Million DKK | -106.94% |
| 2022 FY | -26.33 Million DKK | -26.27% |
| 2022 Q4 | -26.33 Million DKK | 21.34% |
| 2022 Q1 | -13.06 Million DKK | 37.37% |
| 2021 FY | -20.85 Million DKK | -56.76% |
| 2021 Q2 | -31.09 Million DKK | -175.53% |
| 2021 Q3 | -28.37 Million DKK | 8.77% |
| 2021 Q4 | -20.85 Million DKK | 26.49% |
| 2021 Q1 | -11.28 Million DKK | 15.16% |
| 2020 Q2 | -8.18 Million DKK | -15.63% |
| 2020 Q3 | -8.17 Million DKK | 0.18% |
| 2020 FY | -13.3 Million DKK | -80.71% |
| 2020 Q4 | -13.3 Million DKK | -62.76% |
| 2020 Q1 | -7.08 Million DKK | 3.8% |
| 2019 Q2 | -11.5 Million DKK | 13.82% |
| 2019 FY | -7.36 Million DKK | 48.49% |
| 2019 Q3 | -8.74 Million DKK | 23.96% |
| 2019 Q4 | -7.36 Million DKK | 15.81% |
| 2019 Q1 | -13.34 Million DKK | 6.61% |
| 2018 Q1 | -2.26 Million DKK | 67.53% |
| 2018 FY | -14.29 Million DKK | -105.07% |
| 2018 Q4 | -14.29 Million DKK | -116.99% |
| 2018 Q3 | -6.58 Million DKK | 34.3% |
| 2018 Q2 | -10.02 Million DKK | -343.0% |
| 2017 Q1 | -12.92 Million DKK | -7638.32% |
| 2017 Q4 | -6.96 Million DKK | 35.79% |
| 2017 Q3 | -10.85 Million DKK | 8.04% |
| 2017 FY | -6.96 Million DKK | -4073.05% |
| 2017 Q2 | -11.8 Million DKK | 8.67% |
| 2016 Q4 | -167 Thousand DKK | 0.0% |
| 2016 FY | -167 Thousand DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Lipum AB (publ) | -8.46 Million SEK | -2.764% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 82.609% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 54.36% |
| BioArctic AB (publ) | -606.58 Million SEK | 98.566% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 82.579% |
| Mendus AB (publ) | -96.29 Million SEK | 90.966% |
| Genovis AB (publ.) | -43.94 Million SEK | 80.203% |
| CombiGene AB (publ) | -101.44 Million SEK | 91.424% |
| Intervacc AB (publ) | -88.16 Million SEK | 90.133% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 142.413% |
| Active Biotech AB (publ) | -33.2 Million SEK | 73.798% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 116.344% |
| Ziccum AB (publ) | -2.13 Million SEK | -307.066% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.254% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 89.612% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 77.911% |
| Aptahem AB (publ) | 2.9 Million SEK | 399.074% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 97.393% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 93.282% |
| Kancera AB (publ) | -45.69 Million SEK | 80.962% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 97.356% |
| Fluicell AB (publ) | -2.76 Million SEK | -214.839% |
| Saniona AB (publ) | 40.44 Million SEK | 121.507% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 72.753% |
| Biovica International AB (publ) | -58.73 Million SEK | 85.19% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 80.762% |
| AcouSort AB (publ) | -23.98 Million SEK | 63.733% |
| Xintela AB (publ) | -7.8 Million SEK | -11.397% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 70.394% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 105.238% |
| Abliva AB (publ) | -57.24 Million SEK | 84.803% |
| Corline Biomedical AB | -17.01 Million SEK | 48.866% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 89.418% |
| OncoZenge AB (publ) | -12.62 Million SEK | 31.108% |
| Amniotics AB (publ) | -5.63 Million SEK | -54.457% |
| 2cureX AB (publ) | -13.4 Million SEK | 35.097% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 95.532% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -302.545% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 261.093% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 93.703% |
| I-Tech AB | -83.26 Million SEK | 89.552% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 106.458% |
| Cyxone AB (publ) | -16.67 Million SEK | 47.816% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 84.434% |
| Biosergen AB | -1.88 Million SEK | -361.976% |
| Cantargia AB (publ) | -139.74 Million SEK | 93.775% |
| NextCell Pharma AB | -46.79 Million SEK | 81.409% |
| Nanologica AB (publ) | -9.38 Million SEK | 7.339% |
| SynAct Pharma AB | -61.75 Million SEK | 85.914% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 59.379% |
| LIDDS AB (publ) | -13.51 Million SEK | 35.62% |
| BioInvent International AB (publ) | -236.3 Million SEK | 96.319% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -192.699% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 34.244% |
| Alzinova AB (publ) | -21.22 Million SEK | 59.017% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 58.164% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 87.001% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -67.905% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 89.612% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -842.47% |
| Simris Alg AB (publ) | 85.07 Million SEK | 110.225% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 89.403% |